PatternsRadar
Sign in

MANGALAMMangalam Drugs And Organics Limited

NSE
Full chart
31.86INR+2.67 (+9.15%)Close · 6 Oct 2026
12 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹50 CrMarket cap
—P/E (TTM)
59.8%Delivery

Filings & corporate actions

81 results filed
CSV
Next results · Q2 FY27
Expected 9 Nov 2026 – 20 Nov 2026
Estimate: filed 40–51 days after quarter end, last 5 times
Dividend
₹0.50 per share · last 21 Dec 2017
2026
  • 12 AugresultsResults · Q1 FY27 · consolidated and standalone+1.9%NSE
  • 10 JulshareholdingShareholding · 30 Jun 2026+1.8%NSE
  • 14 MayresultsResults · Q4 FY26 · consolidated and standalone-2.0%NSE
  • 17 AprshareholdingShareholding · 31 Mar 2026+0.5%NSE
  • 19 JanshareholdingShareholding · 31 Dec 2025+5.0%NSE
  • 15 JanresultsResults · Q3 FY26 · consolidated and standalone+5.0%NSE

Reaction to results · all yearsrose on day 0 in 30 of 78 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2712 Aug 2026+1.9%-1.2%+27.9%2.6×
Q4 FY2614 May 2026-2.0%-3.7%-3.2%0.8×
Q3 FY2615 Jan 2026+5.0%-0.8%-27.0%1.1×
Q2 FY2620 Nov 2025-4.0%-42.2%-50.3%3.5×
Q1 FY2619 Aug 2025+0.9%-3.4%-7.7%0.2×
Q4 FY2518 May 2025-3.2%-0.2%-1.9%5.4×
Q3 FY2514 Feb 2025-4.4%-7.5%-26.2%0.7×
Q2 FY2515 Nov 2024+1.0%+1.0%+14.5%0.8×
Q1 FY2514 Aug 2024-1.4%+17.8%+19.5%0.5×
Q4 FY2422 May 2024-3.8%-14.2%-10.0%9.4×
Q3 FY2414 Feb 2024+2.1%+9.1%-12.1%1.1×
Q2 FY249 Nov 2023-0.1%-0.6%+0.1%0.2×
Q1 FY2411 Aug 2023-2.9%-4.8%-1.6%1.6×
Q4 FY2331 May 2023-0.9%+0.4%+3.2%0.9×
Q3 FY2314 Feb 2023+1.6%-1.7%+2.3%0.4×
Q2 FY2311 Nov 2022-3.0%-5.5%-0.8%1.1×
Q1 FY236 Aug 2022-2.6%-7.3%-3.8%3.1×
Q4 FY2227 May 2022+7.5%+31.1%+24.6%5.0×
Q3 FY225 Feb 2022-2.1%-10.4%-16.2%0.5×
Q2 FY2213 Nov 2021-5.0%-7.2%-10.9%2.4×
Q1 FY2213 Aug 2021-1.7%-7.4%+0.7%0.4×
Q4 FY2121 May 2021-8.9%-10.4%-1.7%1.4×
Q3 FY2112 Feb 2021-7.2%-18.6%-19.0%4.2×
Q2 FY2113 Nov 2020+5.0%-2.4%-6.5%4.7×
Q1 FY2111 Aug 2020+5.0%+33.9%+52.6%0.7×
Q4 FY2030 Jun 2020-0.3%-10.7%-13.2%1.5×
Q3 FY2024 Jan 2020+4.9%-6.9%-13.7%4.2×
Q2 FY202 Nov 2019+4.9%-8.6%-19.9%0.7×
Q1 FY2027 Jul 2019+4.9%-4.3%-10.6%1.7×
Q4 FY1910 May 2019-3.3%-5.8%-19.8%1.2×
Q3 FY1919 Feb 2019+2.1%+12.9%+41.4%0.5×
Q2 FY1927 Nov 2018-1.9%-4.9%-2.9%0.6×
Q1 FY1931 Aug 2018+1.2%+0.8%-17.1%0.5×
Q4 FY1822 Jun 2018-0.6%-6.6%-24.7%0.3×
Q3 FY1823 Feb 2018+1.7%-3.4%+2.0%1.7×
Q2 FY1823 Nov 2017-1.8%-1.3%+10.1%0.9×
Q1 FY185 Sept 2017-1.1%-1.3%+7.3%0.6×
Q4 FY1730 May 2017+0.4%-1.1%-8.4%1.3×
Q3 FY178 Feb 2017+0.3%-4.1%-3.5%0.7×
Q2 FY1714 Nov 2016-13.5%-19.7%-9.5%1.8×
Q1 FY173 Aug 2016+0.4%+0.9%+0.5%0.3×
Q4 FY1619 May 2016-4.0%-9.2%-23.1%1.5×
Q3 FY1618 Jan 2016-5.0%-10.2%-42.3%0.0×
Q2 FY1623 Oct 2015+1.5%-5.4%+52.9%1.0×
Q1 FY166 Aug 2015-5.0%-0.3%-4.6%1.4×
Q4 FY1521 May 2015-0.2%-8.4%+41.3%0.5×
Q3 FY1528 Jan 2015-6.4%-9.2%-14.7%0.9×
Q2 FY1515 Dec 2014-2.2%+2.2%-3.6%0.4×
Q1 FY1519 Aug 2014+4.9%+18.8%+52.8%3.8×
Q4 FY143 Jun 2014+4.5%+24.5%+62.7%0.0×
Q3 FY1417 Feb 2014-3.7%-21.5%-41.5%0.8×
Q2 FY1425 Nov 2013-4.8%+4.8%+42.9%0.5×
Q1 FY1419 Aug 2013-4.8%-14.3%-29.5%0.0×
Q4 FY1327 May 2013-5.0%-17.4%-36.4%0.0×
Q3 FY131 Mar 2013+4.8%-0.8%-12.7%0.4×
Q2 FY1320 Nov 2012-5.4%-20.8%-16.8%0.1×
Q1 FY133 Aug 2012-6.7%0.0%-22.2%0.6×
Q4 FY1222 May 2012+1.8%+11.4%-15.0%1.2×
Q3 FY1213 Feb 2012-1.2%-3.1%-12.2%0.4×
Q2 FY1211 Nov 2011+0.4%-3.2%-9.7%0.6×
Q1 FY1226 Aug 2011+3.6%+3.6%+9.9%0.2×
Q4 FY114 Jun 20110.0%+0.8%-3.4%0.5×
Q3 FY1110 Feb 2011-0.5%+10.8%+15.0%2.4×
Q2 FY1112 Nov 2010-1.2%-4.3%-22.5%0.5×
Q1 FY1129 Jul 2010-1.5%-1.5%-5.1%0.1×
Q4 FY101 Jun 2010+1.1%+1.5%+0.7%0.5×
Q3 FY1029 Jan 2010-5.0%+0.7%-6.0%0.6×
Q2 FY1028 Oct 2009+1.7%-7.8%-2.2%0.4×
Q1 FY101 Aug 2009+5.4%+1.8%+33.9%1.8×
Q4 FY0918 Jun 2009+2.3%+3.4%-17.2%0.6×
Q3 FY0929 Jan 2009-0.8%-10.0%-11.7%0.5×
Q2 FY0924 Oct 20080.0%-3.5%-25.0%1.3×
Q1 FY0931 Jul 2008-0.8%+4.0%+22.8%0.4×
Q4 FY0820 Jun 2008-3.0%-10.9%-9.4%0.2×
Q3 FY0831 Jan 2008-4.1%+0.6%-9.5%0.1×
Q2 FY082 Nov 2007-1.6%-4.5%+8.4%0.5×
Q1 FY088 Aug 20070.0%-0.3%+9.7%0.5×
Q4 FY0729 Jun 2007+0.6%-3.8%+4.1%0.7×
Average-0.8%-2.6%-2.2%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY-0.4%
Profit YoY—
Interest cost YoY+30.6%
Revenue QoQ-15.1%
Profit QoQ—
CAGR2Y3Y4Y5Y6Y7Y
Revenue+2.4%—————
Profit——————

Key data

CSV
Open29.01
Day range28.98 – 32.00
52-week range22.80 – 73.94
From 52w high-56.9%
RSI (14)53.1
ATR (14)2.22
Volume50.5K
Avg volume (20D)82.4K
Rel volume0.61×
Volatility (1Y)55.7%
Turnover₹16.1L
SMA 50 / 20029.90 / 30.67

Delivery percentage

Latest · 6 Oct 202659.8%
20-day avg67.7%
1-year avg80.6%
Percentile (own history)49th
Range7.3–100.0%
Sessions1,731

Over the last 20 sessions MANGALAM settled 67.7% of its traded quantity, which is unusually high for an NSE equity. Its one-year average is 80.6%, so recent sessions are running 12.9 points lower than usual. The latest session ranks higher than 49% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+9.15%+3.11%+5.15%+14.15%+7.82%-55.88%

Valuation

CSV
Market cap₹50 Cr
P/E (TTM)—
EPS (TTM)-32.88
Shares outstanding1.58Cr
Listed23 May 2005

Ownership

CSV
Promoter35.65%
Promoter Δ QoQ0.00 pp
Public64.35%
FII0.11%
DII0.00%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)49.558.567.357.1
YoY chg-38.0%-34.1%-7.9%-0.4%
Net profit (₹ Cr)(7.3)(9.8)(13.4)(7.6)
YoY chg-373.1%-864.3%-22692.6%—
Net margin-14.8%-16.8%-19.9%-13.4%
EPS-4.64-6.21-8.48-4.83

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 35.65% · public 64.35%
30 Sept 2021: promoter 50.53%31 Dec 2021: promoter 50.53%31 Mar 2022: promoter 50.53%30 Jun 2022: promoter 50.42%30 Sept 2022: promoter 50.42%31 Dec 2022: promoter 50.32%31 Mar 2023: promoter 50.32%30 Jun 2023: promoter 50.32%30 Sept 2023: promoter 50.32%31 Dec 2023: promoter 50.32%31 Mar 2024: promoter 50.32%30 Jun 2024: promoter 50.32%30 Sept 2024: promoter 50.30%31 Dec 2024: promoter 50.30%31 Mar 2025: promoter 50.30%30 Jun 2025: promoter 50.30%30 Sept 2025: promoter 50.30%31 Dec 2025: promoter 35.64%31 Mar 2026: promoter 35.65%30 Jun 2026: promoter 35.65%
2021-092026-06
  • Promoter
  • Public and others
Promoter
35.65%
Public
64.35%
Promoter change
0.00 pp
Filed
10 Jul 2026
FII
0.11%
DII
0.00%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26RQ3 FY26Q4 FY26AQ1 FY27
Revenue from operations0.097.3102.276.579.988.773.057.349.558.567.357.1
Other income0.00.00.00.00.10.10.20.00.00.10.10.1
Total income0.097.3102.376.680.188.873.257.349.658.667.457.2
Total expenses0.097.398.476.078.987.571.670.362.068.480.664.0
└ Finance costs0.03.34.03.73.73.54.04.05.04.13.13.7
└ Depreciation0.03.63.93.94.04.04.74.54.64.54.74.1
Profit before tax0.00.03.90.61.21.41.6(13.0)(12.5)(9.8)(13.3)(6.7)
Tax expense0.0(0.5)0.4(2.1)(1.5)0.11.60.8(5.1)0.00.10.9
Net profit0.00.53.52.72.71.30.1(13.8)(7.3)(9.8)(13.4)(7.6)
EPS0.000.312.231.701.700.810.04-8.72-4.64-6.21-8.48-4.83
Net margin—0.51%3.45%3.51%3.36%1.45%0.08%-24.06%-14.83%-16.82%-19.94%-13.37%
PBT margin—0.04%3.84%0.76%1.50%1.54%2.24%-22.67%-25.16%-16.82%-19.72%-11.81%
Tax rate—-1091.15%10.14%-359.22%-124.18%5.85%96.37%—————

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 12 Aug 2026.

MANGALAM at a glance

  • MANGALAM closed at ₹31.86 on 6 Oct 2026, +9.15% on the day, -55.9% over one year, 56.9% below its 52-week high of ₹73.94.
  • Delivery was 59.8% of traded quantity on 6 Oct 2026, the 49th percentile of its own 1,731 sessions with a reading (20-session average 67.7%, 1-year average 80.6%).
  • Market capitalisation is ₹50 crore, with no positive trailing earnings for a P/E (trailing EPS ₹-32.88).
  • Q1 FY27 results (consolidated, filed 12 Aug 2026): revenue ₹57 crore (-0.4% year on year), net profit ₹-8 crore; the price moved +1.9% on the first session after.
  • Promoters held 35.65% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 9 Nov 2026 and 20 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE584F01014
SeriesEQ
Listed23 May 2005
History from23 May 2005
Sessions5,094

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE